The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Debulking strategies in CLL before venetoclax therapy
Patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) receiving venetoclax may experience tumor lysis syndrome. Ian Flinn, MD, PhD, Tennessee Oncology, Nashville, TN, discusses data from a Phase IIIb trial (NCT03406156) of obinutuzumab monotherapy or bendamustine in treatment naïve patients with CLL/SLL as a debulking strategy. A vast majority of patients achieved low tumor burden after debulking, and achieved an undetectable minimal residual disease status. A successful debulking regimen will increase accessibility to venetoclax for more patients. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
